Get access to more insightful information

By signing up to Upstox today
signup
Shareholding Info
  • Promoters
    46.65 %
  • Foreign institutions-FII
    23.71 %
  • Other domestic institutions
    2.37 %
  • Retail and other
    18.69 %
  • Mutual Funds
    8.59 %

About Glenmark Pharmaceuticals Limited


Glenmark Pharmaceuticals Limited was founded in 1977 by Gracias Saldanha as a generic drug and active pharmaceutical ingredient manufacturer. The company started selling their products initially in the markets of India, Russia and Africa. It went for public issue in 1999.

Even before going public, the company witnessed many significant milestones. In 1979, the company entered the dermatology market with the introduction of Candid Cream. By 1980, it started the export of its products. In 1983, the company established its first manufacturing facility in Nashik, Maharashtra. Its product Ascoril was launched in 1987 and by 1989, the company had expanded its operations to Afghanistan, Sri Lanka, Kenya and Mauritius.

In 1982, the Nashik plant underwent expansion by acquiring an adjacent plot, incorporating the R&D department and increasing the installed production capacity. In 1996, Glenmark Pharmaceuticals Limited formed a wholly-owned subsidiary Glenmark Exports Private Limited to expand its international business. In 1999, the company started marketing its products in Brazil.

Today, Glenmark Pharmaceuticals Limited holds a notable position in the global biopharmaceutical market and is counted among the world's top 100 biopharmaceutical companies. It is also known as one of the top 50 generics and biosimilar companies.

The market capitalisation of Glenmark Pharmaceuticals Limited stood at over ₹25,000 crores as of 24th January 2024. Glenmark Pharmaceuticals share price has moved by close to 80% in the last three years.


Business and Operation


Glenmark Pharmaceuticals engages in the exploration of new molecules, including both new chemical entities (NCEs) and new biological entities (NBEs). It is dedicated to the development, manufacturing and marketing of pharmaceutical products, including formulations and active pharmaceutical ingredients (APIs).

The company is currently advancing multiple molecules through various stages of pre-clinical and clinical development, focussing on the fields of oncology, respiratory and dermatology. Glenmark Pharmaceuticals has a presence across branded, generic and over-the-counter (OTC) segments with a focus on therapeutic areas of respiratory, dermatology and oncology.

The company operates 14 manufacturing facilities located in the US, India, Argentina, Czech Republic and Switzerland. It also has four state-of-the-art research and development centres.

The generics business caters to the needs of developed markets such as the US and Western Europe. The API business distributes products to over 80 countries including the US, various European Union countries, South America and India. The company has also established a significant network with 50 local offices located in over 50 countries.

As of March 31, 2023, Glenmark's portfolio included 183 generic products authorised for distribution in the US market. It also launched eight new products in FY23. In the same fiscal, Glenmark became the first company in India to introduce Indamet in the respiratory segment. Indamet is a type of drug.

During the COVID-19 pandemic, Glenmark Pharmaceuticals entered into a partnership with the Canadian biotech firm SaNOtize Research and Development Corporation to produce and distribute nitric oxide nasal spray in India and various Asian markets. This included countries such as Singapore, Malaysia, Hong Kong, Taiwan, Nepal, Brunei, Cambodia, Laos, Myanmar, Sri Lanka, Timor-Leste and Vietnam.


Financial highlights

  • Glenmark Pharmaceuticals reported revenue for FY23 at ₹12,990 crore as against the value of ₹12,305 crore reported during the previous year.
  • The EBITDA for the company for FY23 was reported at ₹2278.4 crore.
  • The company’s profit after tax for FY23 was reported at ₹377.4 crore as against the value of ₹993.7 crore reported during FY22.
  • The earnings per share was reported at ₹10.53 per share over the previous year value of ₹33.37 per share.
Download Icon Download the Upstox App Today
close

Download Upstox Mobile App

upstox-qr-code